What the Mortality Evidence Shows About MAT

Does medication actually lower the risk of dying?

The research says yes, and it says it clearly. The largest analysis pooling many cohort studies found that people retained on methadone or buprenorphine have substantially lower all-cause mortality and lower overdose mortality than people with opioid use disorder who are not in treatment 1Ref 1Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment (about 11.3 vs 36.1 per 1,000 person-years for methadone), and that risk rises after treatment ends.. This is not a single study or a marketing claim; it is the convergent finding of dozens of studies following tens of thousands of people, which is why national guidelines and federal agencies treat medication as the standard of care rather than one option among equals 2Ref 2National Institute on Drug Abuse (2024).Medications for Opioid Use Disorder.That medications for OUD are an evidence-based standard of care that reduce cravings and withdrawal without producing a high at therapeutic doses — the mechanism linking treatment to reduced return to risky use..

Being on methadone or buprenorphine is associated with a large reduction in the risk of death compared with being out of treatment.

This is framed as evidence, not a promise. No medication removes all risk, and outcomes depend on staying engaged. But the direction and size of the effect are among the most settled facts in the field.

The key numbers, and what they mean

The headline figures come from the pooled cohort analysis, which reports death rates as a rate per 1,000 person-years — a way of counting deaths against how long people were followed. For methadone, all-cause mortality was roughly a third as high during treatment as out of it 1Ref 1Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment (about 11.3 vs 36.1 per 1,000 person-years for methadone), and that risk rises after treatment ends.. The pattern for buprenorphine points the same way: lower risk while in treatment.

In the pooled data, the all-cause death rate was roughly three times higher out of methadone treatment than in it 1Ref 1Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment (about 11.3 vs 36.1 per 1,000 person-years for methadone), and that risk rises after treatment ends..

What these numbers mean in plain terms: the medication is not a small edge. Across large populations, staying in treatment is associated with a difference in survival big enough to see plainly in the data. That is the reason clinicians push back hard when someone wants to leave treatment early.

It is being in treatment that protects you

The survival benefit is tied to retention — to actually staying on the medication — not to having tried it once. The same analysis that found lower death rates during treatment also found that risk climbs again in the period after treatment ends 1Ref 1Sordo L, Barrio G, Bravo MJ, et al. (2017).Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.That retention on methadone or buprenorphine is associated with substantially lower all-cause and overdose mortality than being out of treatment (about 11.3 vs 36.1 per 1,000 person-years for methadone), and that risk rises after treatment ends.. The protective effect travels with engagement; it does not bank permanently after a short course.

That is why anything that keeps people in treatment matters so much. Buprenorphine, at an adequate rather than minimal dose, keeps people in treatment far better than a placebo does 3Ref 3Mattick RP, Breen C, Kimber J, Davoli M (2014).Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.That buprenorphine retains patients in treatment better than placebo at adequate doses — the retention that carries the survival benefit., and retention is the bridge between the medication and the survival numbers. It also reframes the taper question: because leaving is the risky part, coming off is a decision to make carefully, and tapering off mat is worth understanding on its own terms before acting on it.

Medication beat every non-medication path measured against it

When researchers compared multiple treatment pathways head to head, the medication advantage held up against the alternatives people often assume are stronger. A study of nearly 41,000 adults with opioid use disorder compared six pathways and found that only treatment with buprenorphine or methadone was associated with reduced overdose and reduced serious opioid-related emergency care over the following year 4Ref 4Wakeman SE, Larochelle MR, Ameli O, et al. (2020).Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.That among six pathways in 40,885 adults with OUD, only buprenorphine or methadone was associated with reduced overdose and serious opioid-related acute care at 3 and 12 months, while behavioral and residential pathways alone were not.. Intensive behavioral treatment and inpatient or residential programs, on their own, were not.

Among six pathways in 40,885 adults, only buprenorphine or methadone reduced overdose and serious acute care at 3 and 12 months 4Ref 4Wakeman SE, Larochelle MR, Ameli O, et al. (2020).Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.That among six pathways in 40,885 adults with OUD, only buprenorphine or methadone was associated with reduced overdose and serious opioid-related acute care at 3 and 12 months, while behavioral and residential pathways alone were not..

This is a hard finding for a common intuition — that the more intensive, abstinence-focused, residential option must be the most protective. Against the specific outcome of overdose, the data did not support it. This is also the crux of the debate over mat vs abstinence-only approaches: on survival, the medication path is the one the evidence backs.

Why the medication reduces death

The mechanism is not mysterious. At a stable therapeutic dose, methadone and buprenorphine occupy opioid receptors enough to quiet cravings and prevent withdrawal without producing a high, which sharply reduces the drive to return to illicit opioids — the source of most overdose deaths 2Ref 2National Institute on Drug Abuse (2024).Medications for Opioid Use Disorder.That medications for OUD are an evidence-based standard of care that reduce cravings and withdrawal without producing a high at therapeutic doses — the mechanism linking treatment to reduced return to risky use.. Buprenorphine has an additional pharmacological safety feature: a ceiling effect that makes its own respiratory risk lower than a full opioid's. These medications are two of the three approved to treat opioid use disorder 5Ref 5Substance Abuse and Mental Health Services Administration (2021).TIP 63: Medications for Opioid Use Disorder — Full Document.That methadone and buprenorphine are two of the three FDA-approved medications for opioid use disorder..

So the survival benefit is downstream of a simple chain: the medication keeps withdrawal and craving in check, that keeps people from returning to unpredictable street supply, and that is what keeps them alive. It is not that the medication is magic; it is that it removes the day-to-day pressure that otherwise leads back to the most dangerous exposure. Because it does that without impairing function, people can hold down mat and daily life while protected.

What the guidelines conclude

Given evidence of this weight, the clinical guidelines are unambiguous. The national practice guideline recommends treating opioid use disorder with methadone or buprenorphine rather than with withdrawal management alone, states that no medication should be withheld because someone is still using other substances, and holds that medication should not be arbitrarily time-limited 6Ref 6American Society of Addiction Medicine (2020).The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.That the guideline recommends methadone or buprenorphine over withdrawal management alone, that medication should not be withheld for ongoing other-substance use, and that it should not be arbitrarily time-limited.. Each of those positions traces directly back to the mortality data: withholding or prematurely stopping the medication moves a person from the lower-risk column to the higher-risk one.

The practical takeaway is not a directive but a clarity. The survival evidence for MAT is strong, consistent, and specifically about staying in treatment. Whatever else a person weighs — cost, stigma, the daily structure of a methadone program — the mortality question has a clear answer in the research, and it is worth carrying into any conversation with a prescriber.